The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association
Open accessAbstract
Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with increased risk of cardiovascular events that manifest from statin underutilization and discontinuation. The reported frequencies of SAMS are divergent in the literature. The writing group estimates the prevalence of SAMS, namely all muscle symptoms temporally related to statin use but without regard to causality, to be about 10% (range 5% to 25%), and the prevalence of pharmacological SAMS, specifically muscle symptoms resulting from pharmacological properties of the statin, to be about 1-2% (range 0.5% to 4%). In clinical practice, SAMS are likely to result from a combination of pharmacological and nonpharmacological effects, however this does not make the symptoms any less clinically relevant. Regardless of the etiology, SAMS need to be addressed in accordance with patients' preferences and experiences. This clinical perspective reviews the epidemiology and underlying pathophysiology of SAMS, and the cardiovascular consequences resulting from statin discontinuation. We present patient-centered clinical and communication strategies to mitigate SAMS and improve medication adherence and outcomes among statin users. Treatment strategies include 1) optimizing lifestyle interventions, 2) modulating risk factors that may contribute to muscle symptoms, 3) optimizing statin tolerability by dose reduction, decreased dosing frequency, or use of an alternate statin with more favorable pharmacokinetic properties, and 4) use of non-statins, emphasizing those with evidence for atherosclerotic risk reduction, either in combination with or in place of statin therapy depending on the patient's circumstances. The focus of this clinical perspective is sustainable lipoprotein goal achievement, which is important for cardiovascular risk reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent narrative reviews on the management of SAMS found that further research is needed to close the knowledge gap [19].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“18 Patients often experience marked improvement in symptoms within 2-4 weeks following statin discontinuation.”
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“82 , 83 The LDL-C-lowering efficacy is modest, but cholestyramine monotherapy is also proven to reduce the risk of cardiovascular events.”
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationDepression and cardiovascular disease: a clinical review
Hare, D. L., Toukhsati, S. R., Johansson, P., & Jaarsma, T. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht462 · Cited by 1,362
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
Self-citationStatin-Associated Side Effects
Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Covington, A. M., DePalma, S. M., Minissian, M. B., Orringer, C. E., Smith, S. C., Waring, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.006 · Cited by 569
Rumsfeld, J. S., Alexander, K. P., Goff, D. C., Graham, M. M., Ho, P. M., Masoudi, F. A., Moser, D. K., Roger, V. L., Slaughter, M. S., Smolderen, K. G., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182949a2e · Cited by 540
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Self-citationAn assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
Self-citationMoriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Self-citationSafety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Self-citationBanach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al‐Rasadi, K., Aronow, W. S., Athyros, V. G., Djuric, D. M., Владиславович, Е. М., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 386
Cooper‐DeHoff, R. M., Niemi, M., Ramsey, L. B., Luzum, J. A., Tarkiainen, E. K., Straka, R. J., Gong, L., Tuteja, S., Wilke, R. A., Wadelius, M., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2557 · Cited by 366
Anker, S. D., Agewall, S., Borggrefe, M., Calvert, M., Jaime Caro, J., Cowie, M. R., Ford, I., Paty, J. A., Riley, J. P., Swedberg, K., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu205 · Cited by 362
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
Kim, B., Hong, S., Lee, Y., Hong, S. J., Yun, K. H., Hong, B., Heo, J. H., Rha, S., Cho, Y., Lee, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00916-3 · Cited by 341
Nielsen, S. F., & Nordestgaard, B. G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv641 · Cited by 329
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
McGowan, M. P., Dehkordi, S. H. H., Moriarty, P. M., & Duell, P. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013225 · Cited by 293
Self-citationImpact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
De Vera, M. A., Bhole, V., Burns, L. C., & Lacaille, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12339 · Cited by 289
Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 257
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 206
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 201
A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy
Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.016 · Cited by 200
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.022 · Cited by 198
Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197
Self-citationStatin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
Herrett, E., Williamson, E., Brack, K., Beaumont, D., Perkins, A., Thayne, A., Shakur-Still, H., Roberts, I., Prowse, D., Goldacre, B., et al. (2021) · BMJ · doi:10.1136/bmj.n135 · Cited by 191
Qu, H., Guo, M., Chai, H., Wang, W., Gao, Z., & Shi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009835 · Cited by 178 · cited 1×
“72 , 73 One analysis failed to show an increase in statin adherence with CoQ 10 supplementation, which is perhaps a more important outcome measure than pain score improvement.”
Michalska, M., Sahebkar, A., Mikhailidis, D. P., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Hovingh, G. K., Farnier, M., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.118 · Cited by 171
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Palo, K. E. D., Okwuosa, T. M., Przespolewski, E. R., & Sj, D. (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 170
Giral, P., Neumann, A., Weill, A., & Coste, J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz458 · Cited by 167
A clinician's guide to statin drug-drug interactions
Kellick, K. A., Bottorff, M. B., & Toth, P. P. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.010 · Cited by 166
An assessment by the Statin Intolerance Panel: 2014 update
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.002 · Cited by 165
Self-citationFibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety
Shepherd, J. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.1.5 · Cited by 158
Distribution of creatine kinase in the general population: Implications for statin therapy
Brewster, L. M., Mairuhu, G., Sturk, A., & van Montfrans, G. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.008 · Cited by 150
Rosenson, R. S., Miller, K., Bayliss, M. S., Sanchez, R. J., Baccara‐Dinet, M. T., Chibedi-De-Roche, D., Taylor, B. A., Khan, I., Manvelian, G. Z., White, M. K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6723-4 · Cited by 142
Self-citationPenson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12344 · Cited by 110
Statin Discontinuation and Cardiovascular Events Among Older People in Denmark
Thompson, W., Morin, L., Jarbøl, D. E., Andersen, J. H., Ernst, M. T., Nielsen, J. B., Haastrup, P., Schmidt, M., & Pottegård, A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.36802 · Cited by 101
Shared decision‐making for older adults with cardiovascular disease
Backman, W., Levine, S. A., WENGER, N. K., & Harold, J. G. (2019) · Clinical Cardiology · doi:10.1002/clc.23267 · Cited by 95
Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes
Zhang, H., Plutzky, J., Shubina, M., & Turchin, A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-0838 · Cited by 94
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 88
Statin-Associated Muscle Disease: Advances in Diagnosis and Management
Taylor, B. A., & Thompson, P. D. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0670-z · Cited by 85
Creatine kinase in the U.S. population
George, M., McGill, N., & Baker, J. F. (2016) · Medicine · doi:10.1097/md.0000000000004344 · Cited by 77
Brunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 71
Coenzyme Q10 for Patients With Cardiovascular Disease
Raizner, A. E., & Quiñones, M. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.009 · Cited by 66
Jacobson, T. A., Cheeley, M. K., Jones, P. H., Forge, R. L., Maki, K. C., López, J. A. G., Xiang, P., Bushnell, D. M., Martin, M. L., & Cohen, J. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.011 · Cited by 57
Self-citationYetman, H. E., Cox, N., Adler, S. R., Hall, K. T., & Stone, V. E. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.788230 · Cited by 52
Kennedy, C., Köller, Y., & Surkova, E. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.006 · Cited by 51
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
Penson, P. E., & Banach, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab358 · Cited by 48
Scott, R. S., Lintott, C. J., & Wilson, M. J. (1991) · PubMed · Cited by 43
Jones, L. K., Tilberry, S., Gregor, C. M., Yaeger, L., Hu, Y., Sturm, A. C., Seaton, T., Waltz, T. J., Rahm, A. K., Goldberg, A. C., et al. (2021) · Implementation Science · doi:10.1186/s13012-021-01108-0 · Cited by 40
Self-citationStatin-associated muscle symptoms: position paper from the Luso-Latin American Consortium
Sposito, A. C., Faria‐Neto, J. R., de Carvalho, L. S. F., Lorenzatti, A. J., Cafferata, A., Elikir, G. D., Esteban, E., Villegas, E. C. M., Bodanese, L. C., Rodrigo Alonso, K., et al. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1252740 · Cited by 38
Taylor, B. A., Sanchez, R. J., Jacobson, T. A., Chibedi-De-Roche, D., Manvelian, G. Z., Baccara‐Dinet, M. T., Khan, I., & Rosenson, R. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.767 · Cited by 29
Self-citationRiegel, B. J., & Dickson, V. V. (2016) · Heart & Lung · doi:10.1016/j.hrtlng.2016.08.003 · Cited by 28
Statin Denial: An Internet-Driven Cult With Deadly Consequences
Nissen, S. E. (2018) · Annals of Internal Medicine · doi:10.7326/l17-0626 · Cited by 27
Taylor, B. A. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0251-2 · Cited by 22
Duell, P. B., & Connor, W. E. (2008) · Circulation · doi:10.1161/circ.118.suppl_18.s_470 · Cited by 22
Self-citationOkunrintemi, V., Elizondo, J. V., Stone, N. J., Blankstein, R., Blaha, M. J., Gulati, M., Virani, S. S., Zoghbi, W. A., Michos, E. D., & Nasir, K. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100281 · Cited by 19
Vitamin D Supplementation to Treat Statin-Associated Muscle Symptoms: A Review
Lowe, K., Kubra, K. T., He, Z. Y., & Carey, K. (2019) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2019.253 · Cited by 14
Tudor, K., Brooks, J., Howick, J., Fox, R., & Aveyard, P. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007793 · Cited by 9
The value of a specialist lipid clinic
Martin, S. C., & Viljoen, A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01667.x · Cited by 9
Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment
Zaleski, A. L., Taylor, B. A., Pescatello, L. S., Dornelas, E. A., White, C. M., & Thompson, P. D. (2016) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000382 · Cited by 5
Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?
JOY, T. R., & Brennan, E. T. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.008 · Cited by 4
Low-Density Lipoprotein (LDL) Apheresis
Duell, P. B. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_29 · Cited by 3
Self-citationThe clinical lipid specialist. Task Force on Cholesterol Issues, American Heart Association.
LaRosa, J. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1548 · Cited by 1
Ross, J. L. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_34 · Cited by 1
Research works printed but not linked: 1
- Lloyd-Jones, 2022, J. Am. Coll. Cardiol
Cited by
Sorted by citations
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Self-citationAdvances in statin adverse reactions and the potential mechanisms: A systematic review
Zeng, W., Deng, H., Luo, Y., Zhong, S., Huang, M., & Tomlinson, B. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.020 · Cited by 58
“…medication: Major alternative drugs include ezetimib e [110], PCSK9 mAb [111], bempedoic acid [111], inclisiran [112] and evinacumab for homozygous familial hypercholesterolemia [113]; （ III ） combination therapy:Ezetimibe or bempedoic acid + long-acting statin combination [107,110,114,115].”
Metadata
- Authors
- Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B.
- Affiliations
- Oregon Health & Science University (US)
- Duke Medical Center (US)
- Virginia Commonwealth University (US)
- Emory University (US)
- Corresponding author
- Warden, Bruce A.
- Guyton, John R.
- Kovacs, Adrienne C.
- Durham, Jessica A.
- Jones, Laney K.
- Dixon, Dave L.
- Jacobson, Terry A.
- Duell, P. Barton
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 17
- Issue
- 1
- Pages
- 19-39
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W4295221059
- Cited by
- 111
- References
- 82
- Citations by year
- 2026: 24 · 2025: 40 · 2024: 24 · 2023: 21
- FWCI
- 20.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of clinical lipidology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin-associated muscle symptoms, statin intolerance, statin discontinuation, cardiovascular risk, medication adherence, lifestyle intervention, statin dose reduction, non-statin therapy, cardiovascular risk reduction
- MeSH terms
- Humans, Lipids, Muscles, Muscular Diseases, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
